Vanguard Group Inc Nex Immune, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.26 - $0.47 $97,930 - $177,028	-376,657 Reduced 79.47%	97,320 $27,000
Q3 2022 Nov 14, 2022	BUY	$0.6 - $17.5 $16,234 - $473,497	27,057 Added 6.05%	473,977 $263,000
Q2 2022 Aug 12, 2022	BUY	$1.61 - $4.68 $59,037 - $171,610	36,669 Added 8.94%	446,920 $720,000
Q1 2022 May 13, 2022	SELL	$1.79 - $4.65 $487,270 - $1.27 Million	-272,218 Reduced 39.89%	410,251 $1.73 Million
Q4 2021 Feb 14, 2022	BUY	$4.11 - $15.13 $10,796 - $39,746	2,627 Added 0.39%	682,469 $3.15 Million
Q3 2021 Nov 12, 2021	BUY	$10.32 - $16.9 $3.29 Million - $5.38 Million	318,564 Added 88.18%	679,842 $10.3 Million
Q2 2021 Aug 13, 2021	BUY	$14.98 - $23.89 $5.41 Million - $8.63 Million	361,278 New	361,278 $5.9 Million

Ticker NEXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,155,600
Market Cap $7.25M
Description
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's pr...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.